AXSM Trails Peers Into Earnings as Options Turn Bullish

Axsome Therapeutics has drifted 0.4% lower over the past week while its closest specialty pharma peers gained a median 3.4%. TARS rose 9.8% and HRMY added 7.3% over the same period. Even JAZZ managed a 0.9% gain. AXSM's underperformance comes against a steep 22% decline over the past month, leaving the stock at $144.43, more than 40% below the analyst consensus target of roughly $278.

The most striking divergence in the setup is what options traders are doing while the stock slides. The put/call ratio has dropped to 0.58, more than two standard deviations below its 20-day average of 0.79, and close to the 52-week low of 0.48. That is not how a market nervous about a print typically positions. Call volume is running well above its recent norm, suggesting investors are using options to position for a bounce rather than hedge against further downside. The borrow market tells a similar story: availability is loose at roughly 6,000%, meaning there are far more shares available to lend than are currently borrowed, and cost to borrow has eased to 0.29%, down sharply over the past week. Short interest at 6.2% of the free float is meaningful but has been falling, down 5.4% over the week. There is no squeeze pressure here, and there is no aggressive pile-on from new shorts either.

The debate is less about whether Auvelity is working and more about how far its momentum can carry the stock's valuation. The bull case rests on Q2 2026 net revenue of $180.3 million, up 46% year on year, the recent approval for Alzheimer's disease agitation, and near-universal Medicare Part D coverage with minimal prior authorisation hurdles. Analysts are broadly constructive: Piper Sandler, RBC, Deutsche Bank and Truist all carry positive ratings. Truist raised its target sharply in late September. The bear case centres on concentration risk. Sunosi contributed only $33.8 million in Q2 and Symbravo just $2.3 million, leaving the story almost entirely dependent on Auvelity's trajectory. Piper Sandler trimmed its target last week to $238, a signal that even supporters are marking down expectations after the stock's decline. The P/E multiple has compressed by roughly 11 points over the past 30 days, reflecting some of that rethink on valuation.

One institutional detail worth noting: Antecip Capital holds 14% of shares outstanding and has not changed its position, making it a dominant anchor in the register. RTW Investments, by contrast, cut its disclosed stake from 6% to 3.1% in its most recent 13G/A filing, dated August 2025. All insider sales in the trailing 90 days were made under pre-arranged 10b5-1 plans, including a $9.5 million CEO sale in early August, so they carry limited information value as a sentiment signal. Wikipedia page views for the company are running at a z-score of 5.3 against the prior 90 days, indicating a pronounced spike in retail attention heading into today's release.

The print will therefore test whether Auvelity's Q3 revenue trajectory justifies a re-rating back toward the Street's targets, or whether the month-long selloff has correctly repriced what is still a heavily concentrated commercial story.